From Bench to Bedside—An Example of an In Situ Hydrogel in In Vivo Applications - In-Situ Gelling Polymers: For Biomedical Applications - page 220

12.5 % whereas the standard of care group had 20 % response. A clearer differen-
tiation between the two groups was provided by the pCR, where only 12.5 % of
patients in the control arm experienced pCR as compared to 27.7 % response in
the control group.
It is well established that systemic administration of paclitaxel increases the
efficacy of chemo radiotherapy, thus the lack of significant improvement shown
by this combined study was attributed to the localized delivery of paclitaxel in the
form of an Oncogel™. Since Oncogel™ failed to show a significant improvement
in the efficacy, it was terminated as a potential therapy for esophageal cancer in
2010 [ 25 ].
References
1. Park, M.H., Joo, M.K., Choi, B.G., Jeong, B.: Biodegradable thermogels. Acc. Chem. Res.
45 (3), 424-433 (2012). doi: 10.1021/ar200162j
2. Jeong, B., Kim, S.W., Bae, Y.H.: Thermosensitive sol-gel reversible hydrogels. Adv. Drug
Deliv. Rev. 64 , 154-162 (2012). doi: 10.1016/j.addr.2012.09.012
3. Ko, D.Y., Shinde, U.P., Yeon, B., Jeong, B.: Recent progress of in situ formed gels for bio-
medical applications. Prog. Polym. Sci. 38 (3-4), 672-701 (2013). doi: 10.1016/j.progpolym
sci.2012.08.002
4. Zentner, G.M., Rathi, R., Shih, C., McRea, J.C., Seo, M.H., Oh, H., Rhee, B.G., Mestecky,
J., Moldoveanu, Z., Morgan, M., Weitman, S.: Biodegradable block copolymers for deliv-
ery of proteins and water-insoluble drugs. J. Controlled Release 72 (1-3), 203-215 (2001).
doi: 10.1016/s0168-3659(01)00276-0
5.Elstad, N.L., Fowers, K.D.: OncoGel (ReGel/paclitaxel)—clinical applications for
a novel paclitaxel delivery system. Adv. Drug Deliv. Rev. 61 (10), 785-794 (2009).
doi: 10.1016/j.addr.2009.04.010
6. DuValla, G.A., Tarabar, D., Seidela, R.H., Elstad, N.L., Fowers, K.D.: Phase 2: a dose-esca-
lation study of OncoGel (ReGel/paclitaxel), a controlled-release formulation of paclitaxel,
as adjunctive local therapy to external-beam radiation in patients with inoperable esophageal
cancer. Anticancer Drugs 20 (2), 89-95 (2009). doi: 10.1097/CAD.0b013e3283222c12
7. Bagley, C.A., Bookland, M.J., Pindrik, J.A., Ozmen, T., Gokaslan, Z.L., Witham, T.F.: Local
delivery of OncoGel delays paresis in rat metastatic spinal tumor model. J. Neurosurg. Spine
7 (2), 194-198 (2007). doi: 10.3171/spi-07/08/194
8. Gok, B., McGirt, M.J., Sciubba, D.M., Garces-Ambrossi, G., Nelson, C., Noggle, J., Bydon,
A., Witham, T.F., Wolinsky, J.P., Gokaslan, Z.L.: Adjuvant treatment with locally delivered
OncoGel delays the onset of paresis after surgical resection of experimental spinal column
metastasis. Neurosurgery 65 (1), 193-200 (2009). doi: 10.1227/01.neu.0000345948.54008.82
9. Ramalingam, S., Belani, C.P.: Basic treatment considerations: chemotherapy. Hematol.
Oncol. Clin. North Am. 18 (1), 13-28 (2004). doi: 10.1016/s0889-8588(03)00136-9
10. Safran, H., Akerman, P., Cioffi, W., Gaissert, H., Joseph, P., King, T., Hesketh, P.J., Wanebo,
H.: Paclitaxel and concurrent radiation therapy for locally advanced adenocarcinomas of the
pancreas, stomach, and gastroesophageal junction. Semin. Radiat. Oncol. 9 (2), 53-57 (1999)
11. Matthes, K., Mino-Kenudson, M., Sahani, D.V., Holalkere, N., Fowers, K.D., Rathi, R.,
Brugge, W.R.: EUS-guided injection of paclitaxel (OncoGel) provides therapeutic drug
concentrations in the porcine pancreas (with video). Gastrointest. Endosc. 65 (3), 448-453
(2007). doi : 10.1016/j.gie.2006.06.030
12. Duvall, A., Tarabar, D., Seidel, R.H., Doder, R., Elstad, N.L., Fowers, K.D.: Phase 2a dose
escalation trial of OncoGel (R) (Regel (R)/Paclitaxel) as adjunctive local therapy to external